RAC 1.27% $1.55 race oncology ltd

Sorry, mate. I don't think I answered you correctly. Biomarkers:...

  1. 1,036 Posts.
    lightbulb Created with Sketch. 11622
    Sorry, mate. I don't think I answered you correctly.

    Biomarkers: Something like tumor DNA damage markers for lead in single agent and combination.

    Clinical Responses: Complete and partial responses, and progression free survival.

    Clinical responses can be correlated with biomarker activity to determine synergism. Comparing clinical responses for the combination can be made to known populations with similar demographics who have received single-agent Dox at equivalent dosing. There should be a fair amount of information available for Doxorubicin to compare the combination to. For example, here is a paper that evaluated single-agent doxorubicin in anthracycline naive second-line metastatic breast cancer patients.

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150384/pdf/brjcancer00088-0203.pdf
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.55
Change
-0.020(1.27%)
Mkt cap ! $264.0M
Open High Low Value Volume
$1.59 $1.62 $1.51 $218.3K 138.7K

Buyers (Bids)

No. Vol. Price($)
1 95 $1.53
 

Sellers (Offers)

Price($) Vol. No.
$1.55 157 1
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.